Search This Blog

Monday, December 31, 2018

Huge Garbage Pile At NYCHA Building Creates Awful Stench


garbage2 1 Huge Garbage Pile At NYCHA Building Creates Awful Stench
The Department of Sanitation and NYCHA workers arrived on the scene Sunday evening, but not before massive piles of garbage sat around and rotted for days.
“It really stinks. It’s horrible,” Iris Rojas said.
“It smells like a bunch of cabbage and lot of dirty diapers. Nasty,” Bella Rojas added.
The odor was so pungent Iris Rojas rushed her young daughter away in the middle of our interview.
“Cover your nose. Come on, I feel like there’s something in the air,” she said. “We have to get going. It smells.”

People who live here say the collection area on Watson Avenue near Beach Avenue is often unpleasant, but not usually like this.
“I’m not surprised because it’s always very stinky over here. Trash always looks like it’s going to go up into the trees,” Sotomayor Houses resident Jordan Robinson said. “But this is the worst I’ve seen.”

An emergency team of NYCHA and Department of Sanitation workers were on the scene Sunday night, just hours after Bronx Borough President Ruben Diaz Jr. tweeted a video.
Embedded video
Ruben Diaz Jr.
✔@rubendiazjr
Hey @NYCHA @NYCMayor, how about we try to start the new year off right for the tenants of the Sotomayor Houses?
These are disgusting, unacceptable conditions that foster rats and vermin infestations. This needs to be cleaned ASAP.   
“Somebody in City Hall just doesn’t care,” Diaz said. “Have the New York City Housing Authority do their job.”
A NYCHA spokesperson told CBS2’s Roy the trash compactors at the housing complex have been broken, causing the pileup.
In an interview with WNYC Radio on Friday. Mayor Bill de Blasio acknowledged more needs to be done in the new year for NYCHA residents.
“The situation for our public housing residents is not what it should be,” de Blasio said. “It’s unacceptable to me. We made a lot of investments. We’ve made a lot of changes. We have new leadership, but we’ve got to turn the corner in 2019.”
A NYCHA spokesperson said while the machines are being repaired the agency will be keeping a close eye on this garbage collection area to make sure it doesn’t build up like this again.

Aristea Therapeutics Raises $15M to Develop Anti-Inflammatory Drugs


New biopharma company Aristea Therapeutics has raised $15 million from Novo Holdings, the Danish investment company, and secured global rights to an investigational AstraZeneca drug that’s ready for Phase 2 study.
The San Diego, CA, company made its public debut this week after starting up quietly earlier this year.
Aristea expects its lead program, RIST4721, the drug candidate it licensed from AstraZeneca, will enter a Phase 2 clinical trial early next year. The company also plans to develop drugs to tackle serious inflammatory diseases, although it hasn’t identified which it is aiming to treat.
The company’s CEO is James Mackay, an AstraZeneca (NYSE: AZN) veteran who was named president and chief operating officer of San Diego’s Ardea Biosciences following its 2012 acquisition by the UK-based biopharma giant for $1.26 billion.
Mackay later became CEO of Ardea, which had developed a drug for gout, a type of inflammatory arthritis. However, by the time the FDA gave its approval to the drug, lesinurad (Zurampic)—which reduces the abnormally high levels of uric acid associated with gout—AstraZeneca had decided it wasn’t interested in keeping treatments for the disease in its portfolio.
Instead, AstraZeneca in 2016 licensed lesinurad to Cambridge-based Ironwood Pharmaceuticals (NASDAQ: IRWD) for U.S. use and to German drugmaker GrĂ¼nenthal for Europe and Latin America and began laying off employees in San Diego ahead of a full shutdown planned for early 2018.
Ironwood struggled to sell the drug, and this year said it would end the license agreement.
Novo Holdings has an ownership stake in Danish biotech Novo Nordisk (NYSE: NVO) and manages the Novo Nordisk Foundation’s endowment. As part of the Aristea financing deal, Novo’s Tiba Aynechi and Ken Harrison have joined the company’s board of directors.

Nobilis taps former Memorial Hermann exec as new CEO


https://www.bizjournals.com/houston/news/2018/12/27/houston-health-care-co-taps-former-memorial.html

SunTrust Leads $86M in Financing for $300M Atlanta Seniors Living Project


SunTrust BankFirst Tennessee Bank and Pinnacle Bank have combined to provide $86 million in construction debt to Village Park Senior Living for the first phase of development on a planned $300 million luxury seniors living project in Atlanta, according to information from SunTrust.

SunTrust, in leading the transaction, provided roughly $48 million, while First Tennessee and Pinnacle Bank provided approximately $20 million and $18 million, respectively, according to a spokeswoman for SunTrust. The deal closed in October. (The bank would not provide the exact date.)
The financing for phase two and three of the development has yet to be determined, according to a SunTrust spokeswoman.
“As an industry, we have limited supply and a growing demand for exclusive senior living communities throughout the country,” Village Park Senior Living CEO Tim Gary said in a prepared statement. “The Atlanta population is booming. Many professionals are moving to the city and bringing their parents along with them. This community will deliver on the highest quality of service and care for our residents.”
The project is currently being referred to as Village Park Paces; the formal name hasn’t been announced yet. Construction on phase one of the 9-acre campus, which will be at 3200 Howell Mill Road NW, is scheduled to wrap in spring 2020, according to Village Park’s website. SunTrust indicated that it expects the first phase of development to be completed by fall 2020.
LR Village Park Paces Courtyard lower SunTrust Leads $86M in Financing for $300M Atlanta Seniors Living Project
A RENDERING OF VILLAGE PARK PACES’ LOWER COURTYARD. COURTESY: SUNTRUST BANK
Phase one will see construction of 204 of the 600 planned units—82 independent living, 75 assisted living, 26 memory care units and 21 “city homes” with a separate entrance—as well as most of the project’s common areas.
The development will sport French-inspired architecture with landscaped courtyards and will include a movie theater, a florist, a library, a salon, a wine bar, a sports bar and an outdoor pool.
The typical size of new seniors housing development projects has grown nearly 5 percent this year, and the cost of developing these projects has climbed in lockstep. The total cost of constructing seniors housing this year has increased by just over 5 percent to an average of $298 per square foot, or $270,200 per unit, according to a third quarter report from CBRE.
Since the fourth quarter of 2017, new construction has fallen across all seniors housing segments—independent, assisted living and memory care and skilled nursing—according to a separate third quarter CBRE seniors housing report and survey focused on investor sentiment. Still, investor interest in the sector is strong, as CBRE indicated that many players are showcasing more confidence in the lifestyle-focused segments of independent and assisted living and are planning to grow their respective portfolios through the first half of 2019.

Fentanyl testing kits could help save lives


Cities across the country are distributing drug testing kits hoping to save lives. Fentanyl test strips can check to see if drugs contain fentanyl, a powerful and deadly painkiller almost instantly.
Fentanyl is being added to many street drugs to increase the high and it is also increasing death rates. People are overdosing at record numbers.
Using the test kits are simple — someone can put their heroin, cocaine, or even weed, in a cup and stick in a strip. The small test strip goes into the mix and depending on how many red lines you see, fentanyl has been detected.
Researchers at Johns Hopkins University found most users want to know if their drugs have fentanyl and many would change their behavior if they knew. Dealers are lacing all sorts of drugs with fentanyl because it’s cheaper and gives users a better high, but it’s so powerful it is killing people.
So could these testing kits make a difference in our area? Gates Police Chief James VanBrederode said if used correctly, it might.
“It’s a great idea for some people and some people might take the time to do it,” VanBrederode said. “But I think you’ll see it’s a very small minority of people that are going to do this.”
Jim Wesley, a former crime lab technician and drug prevention educator, said he thinks the kits could save lives, but should be carefully distributed.
“I think you would have to sit down with a committee and come up with a campaign to explain the limitations and the benefits,” Wesley said. “This is not something that’s going to be used to buy more fentanyl.”
Some officials in cities including Baltimore, Columbus, and Philadelphia have started giving these tests along with clean needles. Right now, these kits are not being distributed in our area but anyone can order them online. They cost anywhere from $1 to $3 each.

'I Had To Quit For My Sanity': Teachers Resigning At Highest Rate Ever Recorded

Teachers and other public education employees are quitting their jobs at the fastest pace on record after roughly 10% of the industry quit over a 12 month period ending in October, according to data from the Labor Department.

While US workers overall at the highest rate since 2001 amid a tight labor market and historically low unemployment, quitting a job in education is notable since the field is known for stability and rewarding longevity, reports the Wall Street Journal's Michelle Hackman and Eric Morath.
 

 
The educators may be finding new jobs at other schools, or leaving education altogether: The departures come alongside protests this year in six states where teachers in some cases shut down schools over tight budgets, small raises and poor conditions.
In the first 10 months of 2018, public educators quit at an average rate of 83 per 10,000 a month, according to the Labor Department. While that is still well below the rate for American workers overall—231 voluntary departures per 10,000 workers in 2018—it is the highest rate for public educators since such records began in 2001. -WSJ

Sara Jorve, a 43-year-old fifth-grade math and science teacher from Oklahoma, protested alongside other teachers last spring for better pay and classroom conditions - eventually quitting in May after a dozen years as an educator. Jorve, a single mother, said she had to rely on her parents for financial assistance due to the meager pay - though she returned during the summer to become a cardiovascular ultrasound technician.
"I had to quit for my sanity," said Jorve.
The rising number of departures among public education workers is in contrast with 2009, when the economy was first emerging from a deep recession. Then, the rate was just 48 per 10,000 public education workers, a record low.
During the recession, education was a safe place to be,” said Julia Pollak, labor economist at ZipRecruiter.
That year, the unemployment rate touched 10%, the highest since the 1980s. This year, the jobless rate fell to 3.7%, the lowest reading since 1969. That has created very different incentives for teachers and their public education colleagues.
It’s a more boring place now, and they see their friends finding exciting opportunities,” Ms. Pollak said. -WSJ
Since 2015 school districts have reported a shortage of qualified teachers to fill open slots, which resulted in more states opening temporary teaching jobs to underqualified applicants, according to the Learning Policy Institute. Qualified teachers leaving the field at a record pace will likely exacerbate that trend, according to the Journal.
 
In the 12 month period ending in October, one million people quit the public education sector according to the most recent Labor Department data, out of more than 10 million Americans in the field.
Compounding the situation is the fact that while the private-sector largely recovered from the recession years ago, education workers are still feeling the effects - as funding for public education across several states still hasn't recovered from cuts made during the downturn.
Public education budgets are down at least 7% from 2009 levels in at least 12 states, adjusting for inflation, according to the left-leaning Center on Budget and Policy Priorities - which analyzed census data. Meanwhile, teacher pay is now 5% lower than it was in 2009 according to data from the National Education Association - the largest teachers union in the country.

Wages and salaries for public-education workers rose 2.2% in the third quarter from a year earlier, not adjusting for inflation. That matched the largest annual raise in nearly a decade, but was still well below the 3.1% annual increase in pay private-sector workers received in the third quarter, according to the Labor Department. -WSJ
Also putting the squeeze on teachers are those who took out expensive student loans to get master's degrees.
Teachers have been striking across the country over low pay and per-pupil funding levels - in some cases resulting in classroom shutdowns for as many as nine school days. The result? Some teachers achieved moderate gains in the states where the strikes occurred; with teachers in West Virginia, Oklahoma and Arizona all receiving raises.
The protests also spotlighted the dismal state of the educational system.
"Part of it was compensation," said Alice Cain EVP of Teach Plus - a policy organization that works with a network of 26,000 teachers. "But part of this was that their students weren’t valued, and that the public education system in our country isn’t a priority in so many places."
https://www.zerohedge.com/news/2018-12-30/i-had-quit-my-sanity-teachers-resigning-highest-rate-ever-recorded

Mycenax’s Actemra biosimilar edges closer to approval


Mycenax’s biosimilar of Roche’s Actemra (tocilizumab), LusiNEX, has been shown to match its originator’s profile in a phase I PK trial, meaning it is on track to become the first approved biosimilar for the drug.
Actemra, marketed as RoActemra in the EU, is approved for immunology and musculoskeletal disorders including rheumatoid arthritis.
The double-blinded, randomized, 3-arm parallel study was conducted in Australia and New Zealand. Three randomized groups of 190 healthy subjects received single intravenous dose (4 mg/kg) of either LusiNEX or originator products (EU-RoActemra or US-Actemra). After dosing, study participants underwent an 8-week assessment period to evaluate its bioequivalence in terms of pharmacokinetic (PK), safety and tolerability.
The study’s primary endpoint was the area under the concentration-versus-time curve calculated from start of the infusion until infinity (AUC 0-inf). The study’s prespecified bioequivalence margin was 80% to 125%.
The results demonstrated that LusiNEX met its primary endpoint in PK comparison (AUC0-inf). The geometric mean ratio was 96.60 % (90 % CI, 92.33 % – 101.06 %) and 95.58 % (91.30 % – 100.07 %) compared with EU and US originators, respectively. Other PK parameters and the types and incidence rates of adverse events observed with LusiNEX were also comparable to those seen with the originator products.
“We are planning to apply for the scientific advises to European Medicines Agency and Japan Pharmaceuticals and Medical Devices Agency in the first quarter of 2019 to finalise the multinational phase 3 study design with the goal of being granted for both intravenous and subcutaneous dosage forms,” said Karen Wen, president at Mycenax Biotech.
Actemra is a recombinant humanized anti-IL-6R monoclonal antibody for injection. Interleukin-6 (IL-6) triggers its signaling system through binding to 80 kDa transmembrane IL-6 receptor (IL-6R). After binding to IL-6R, the complex consisting of IL-6 and transmembrane IL-6R associates with signal-transducing molecule gp130, resulting in the activation of downstream signaling events via Janus kinase (JAK) in target cells. Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R) and therefore inhibits the inflammatory signaling that implicated in the pathogenesis of diseases.